Expression of E-cadherin in primary prostate cancer: correlation with clinical features

British Journal of Urology
M A KuczykU Jonas

Abstract

To correlate the immunohistochemically detected loss of E-cadherin expression with patient age, clinical and biological variables, and to investigate the prognostic value of these variables for the relapse-free and overall survival of patients with different stages of newly diagnosed prostate cancer. Sixty-seven patients (median age 63 years, range 48-78) undergoing radical prostatectomy for the treatment of primary prostate cancer were assessed to determine whether age, tumour stage, histological grading, serum levels of prostate specific antigen and prostatic acid phosphatase, regional lymph node status and E-cadherin expression were prognostic factors for relapse-free and overall survival. With a median (range) follow-up of 54 (3-193) months, there was no independent prognostic value of decreased E-cadherin expression for the long-term or recurrence-free survival of patients, using a threshold value of 40% for the relative amount of positively stained tumour cells, or for any other threshold value calculated (25%, 60% or 75%). However, comparing a follow-up of 16 months in patients with < 40% positivity and 46 months in patients with > or = 34% positivity, those patients retaining E-cadherin expression had a significantly lo...Continue Reading

References

Oct 1, 1992·British Journal of Cancer·M PignatelliM Takeichi
Feb 1, 1992·British Journal of Urology·J AdolfssonT Löwhagen
Jun 1, 1991·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·S R ShiK L Kalra
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·G M EdelmanJ P Thiery
Feb 1, 1995·Journal of Clinical Pathology·R E BanksP J Selby
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·I TammJ G Krueger
Jan 1, 1993·CA: a Cancer Journal for Clinicians·C C BoringT Tong
Jan 1, 1997·American Journal of Clinical Pathology·M B CohenJ S Ross

❮ Previous
Next ❯

Citations

Aug 17, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S LoricP Eschwège
Nov 9, 2000·BJU International·W D DunsmuirR S Kirby
Nov 19, 2011·Prostate Cancer·Gregory P Swanson, David Quinn
Nov 29, 2012·Journal of Cancer Research and Clinical Oncology·Naveen Kachroo, Vincent J Gnanapragasam
Jul 16, 2005·Scandinavian Journal of Urology and Nephrology. Supplementum·Jonathan I EpsteinRodolfo Montironi
Sep 2, 2006·Critical Reviews in Oncology/hematology·H G van der Poel
Oct 10, 2001·The Urologic Clinics of North America·J I Epstein
Apr 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David I QuinnRobert L Sutherland
Jun 28, 2011·The American Journal of Pathology·Aaron P PutzkeBeatrice S Knudsen
Mar 10, 2001·The Journal of Pathology·K EndoT Terada
Nov 24, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Dinesh S RaoJonathan W Said
Jul 17, 1999·British Journal of Cancer·B P WijnhovenW N Dinjens
May 8, 2003·Journal of the National Cancer Institute·Daniel R RhodesMark A Rubin
Feb 13, 2003·The Journal of Pathology·Michael D SlaterJulian A Barden
Feb 1, 2017·The Journal of Pathology. Clinical Research·Boris DasenMaria Philippova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.